|
Getting your Trinity Audio player ready...
|
Fifty Years of Data —
and What It Actually Shows
Carbohydrate intake, antihypertensive polypharmacy and cardiovascular mortality in the USA, 1971–2021. Prevalence trajectories across five decades of NHANES surveillance data.
As carbohydrate intake rose after 1977 dietary guidelines, hypertension and type 2 diabetes surged. Drug prescribing escalated to suppress cardiovascular deaths — but the underlying insulin resistance deepened unchecked. Death was deferred. The root cause was never addressed.
Well-intentioned dietary guidelines have recommended high carbohydrate intake for generations. For the majority of people, this has proved counter-therapeutic. Carbohydrates drive insulin secretion. Years of elevated insulin produce insulin resistance — the metabolic root cause of hypertension, type 2 diabetes, cardiovascular disease, and much of the chronic disease burden we see today.
What Fifty Years of Data Actually Shows
For half a century, cardiovascular disease has been described as a problem medicine is winning. Death rates from heart attack and stroke have fallen dramatically since the 1970s. Statins, antihypertensive drugs, coronary stents, clot-busting thrombolytics — these interventions have collectively kept millions of people alive who would otherwise have died. This is a genuine achievement, and it should not be dismissed.
But the data tells a more troubling story. Because while cardiovascular death rates fell, something else was quietly rising — and has not stopped rising. The number of people requiring medication to control their blood pressure grew year on year. The number requiring two drugs, then three, then four or more, grew with it. And threading through all of it, rising in almost perfect parallel, is dietary carbohydrate intake.
The Correlation the Data Reveals
When you plot carbohydrate intake as a percentage of total energy against the prevalence of hypertension across fifty years of NHANES data, the Pearson correlation coefficient is r = 0.67. When you plot it against type 2 diabetes prevalence, r = 0.61. These are not weak associations. They track across five decades of independent surveillance data, collected by different agencies using different methodologies, and they point in the same direction.
When you add antihypertensive drug use to the picture, the correlation with carbohydrate intake is r = 0.62 for any antihypertensive use, and r = 0.56 for the harder-to-treat patients requiring three or more drugs simultaneously. As dietary carbohydrate intake rose following the 1977 US Dietary Guidelines — which recommended 55–60% of calories from carbohydrates and sharply reduced fat — the population needing pharmaceutical intervention to manage blood pressure grew in near-lockstep.
Hypertension prevalence
Type 2 diabetes prevalence
Any antihypertensive use
CVD/stroke mortality
The correlation between antihypertensive polypharmacy and falling cardiovascular mortality is r = −0.97. As the drug burden grew, the death rate fell — almost perfectly. This is not evidence of a problem solved. It is evidence of a problem suppressed.
Pearson r values calculated from NHANES surveillance data 1971–2021. A negative r for CVD/stroke mortality reflects the pharmaceutical masking effect — not metabolic improvement. As the drug burden grew, it suppressed the downstream outcome while the upstream cause continued to progress.
The solid gold line shows carbohydrate intake rising from the 1970s. The navy dashed line shows the percentage of adults on any antihypertensive medication growing in parallel. The red line shows CVD and stroke deaths per 100,000 falling over the same period.
The falling death rate does not indicate improving metabolic health. A landmark analysis by Ford et al. (New England Journal of Medicine, 2007) estimated that approximately 47% of the decline in coronary heart disease deaths between 1980 and 2000 was directly attributable to medical interventions — statins, antihypertensives, stents, and thrombolytics. The remaining decline reflected improvements in smoking rates and physical activity, not dietary change.
The r = −0.97 correlation between polypharmacy and falling mortality makes this precise: as the drug burden escalated, deaths were suppressed with near-perfect efficiency. But the metabolic disease burden — hypertension, type 2 diabetes, metabolic syndrome — continued to rise throughout. Death was deferred. The problem was not solved.
What This Does and Does Not Mean
It would be tempting to read the falling death rate as a success story: drugs worked. But this interpretation contains a critical error of reasoning. Consider what the drug burden itself represents. A person requiring three, four, or five antihypertensive medications is not a person whose cardiovascular health is under control. They are a person whose underlying disease is severe enough that it cannot be managed with fewer drugs.
They carry a substantially elevated lifetime risk of heart failure, kidney failure, stroke, and cardiac death — risks that increase with each additional drug class required, as large-scale registry studies have confirmed. The drug burden is not a measure of health. It is a measure of how advanced the underlying pathology has become.
What the data shows, viewed honestly, is this: over fifty years, a dietary environment high in refined and processed carbohydrates produced a progressive increase in insulin resistance across the population. Insulin resistance drove hypertension through well-established mechanisms — renal sodium retention, activation of the renin-angiotensin-aldosterone system (RAAS), increased sympathetic nervous system tone, and endothelial dysfunction. It simultaneously drove the epidemic of type 2 diabetes, metabolic syndrome, and visceral adiposity that are the recognised precursors of cardiovascular disease.
The Root Cause That Was Never Addressed
Throughout this entire fifty-year period, insulin resistance — the metabolic state that precedes and drives hypertension, type 2 diabetes, dyslipidaemia, chronic inflammation, and ultimately cardiovascular disease — continued to worsen silently in the population. It worsened because the dietary advice that millions followed in good faith directed them toward the precise macronutrient pattern most likely to sustain and deepen insulin resistance: high carbohydrate, low fat, frequent eating.
Insulin resistance is not measured in standard clinical practice. Blood pressure is measured. Cholesterol is measured. Blood glucose is measured — but usually only late, when type 2 diabetes is already established. The earlier, more sensitive marker — fasting insulin and the HOMA-IR score derived from it — is rarely if ever ordered. This means that for most people, the root cause remains unmeasured, unnamed, and unaddressed, while its consequences are managed with an expanding stack of medications.
The growing polypharmacy burden visible in these graphs is not evidence of medical failure. It is evidence of a system doing the best it can with the tools available to it, treating consequences rather than causes. The number of people on five, six, seven, or eight antihypertensive medications represents the far end of a spectrum that began decades earlier with a dietary pattern that progressively eroded metabolic resilience.
The Advice That Pointed in Exactly the Wrong Direction
For decades — and in many official guidelines still today — the dietary message has been consistent: eat more carbohydrates. Reduce fat. Base your meals on bread, pasta, rice, cereals, and starchy vegetables. This message has been promoted by governments, health authorities, nutritional charities, and medical practitioners on both sides of the Atlantic as the foundation of a heart-healthy diet.
It is precisely the opposite of what reduces insulin resistance.
Carbohydrates — particularly refined and high-glycaemic carbohydrates — are the primary dietary driver of postprandial insulin secretion. Every time blood glucose rises in response to a carbohydrate-containing meal, the pancreas secretes insulin to clear that glucose from the bloodstream. In a metabolically healthy person, this system functions efficiently. But in a person with developing or established insulin resistance, the cells have become progressively less responsive to insulin's signal. The pancreas compensates by secreting more insulin still. Fasting insulin rises. HOMA-IR rises. And chronically elevated insulin — hyperinsulinaemia — becomes the metabolic state in which the body now operates.
A high-carbohydrate diet does not cause insulin resistance in a single meal or a single week. It causes it across years and decades of repeated postprandial insulin spikes, gradual receptor desensitisation, accumulating visceral fat, and progressive loss of metabolic flexibility. The damage is slow, cumulative, and almost entirely invisible in standard clinical testing — until it is not.
This is why the dietary advice of the past fifty years has been so consequential. It was not merely neutral. It was actively counter-therapeutic for the majority of people who followed it, because it systematically sustained the hormonal environment in which insulin resistance deepens. The more faithfully someone followed official guidance — more wholegrains, fewer eggs, less saturated fat, more fruit, more frequent small meals — the more reliably they maintained the elevated insulin levels that, over time, drive the conditions this entire series documents.
The standard response to this argument is that quality of carbohydrate matters — that wholegrains, legumes, and complex carbohydrates are metabolically different from refined sugar and white flour. This is partially true. Wholegrain carbohydrates raise blood glucose more slowly. Their glycaemic index is lower.
But for a person who is already insulin resistant — and the data in this series suggests that is the vast majority of adults over 45 — even a moderate glycaemic response still triggers an insulin response that their cells are unable to answer efficiently. The fasting insulin does not fall. The HOMA-IR does not improve. The pancreas continues to overcompensate. The metabolic environment of insulin resistance persists.
The distinction between refined and unrefined carbohydrates matters at the margins. It does not resolve the underlying problem for the majority of people for whom insulin resistance is already established. Reducing carbohydrate intake substantially — not merely improving its quality — is what lowers fasting insulin, reduces postprandial glucose excursions, and allows insulin sensitivity to recover.
This is not a fringe position. It is supported by the mechanistic literature on insulin physiology, by the clinical outcomes data from very low carbohydrate and ketogenic dietary interventions, and by the straightforward logic that the primary dietary stimulus for insulin secretion is carbohydrate. Reducing that stimulus is the most direct dietary lever available for reducing insulin resistance.
The trajectory shown in the graph above — carbohydrate intake rising, hypertension rising, antihypertensive prescribing rising — is not a coincidence. It is the predictable population-level consequence of dietary guidelines that, for the best of intentions, pointed millions of people toward exactly the food group most likely to sustain the condition at the root of their cardiovascular risk.
For the vast majority of people, a high-carbohydrate diet is not a neutral dietary choice. For anyone with measurable insulin resistance — and the epidemiological evidence suggests that is most adults in the developed world — it is a dietary pattern that actively sustains their disease.
What the Graphs Cannot Show
There is one thing these population-level correlations cannot capture, and it is worth stating plainly. They cannot show what would have happened if insulin resistance had been identified and addressed at the root. They cannot show the individual whose HOMA-IR of 4.2 at age 45 eventually became hypertension at 52, then a second antihypertensive at 56, then a third at 60, then a cardiac event at 65. They show the aggregate. The individual trajectory is invisible in population statistics.
That individual trajectory is precisely what a HOMA-IR test, taken before the clinical consequences have accumulated, has the potential to interrupt. Not by adding another drug, but by identifying the metabolic state that, if left uncorrected, makes the drugs increasingly necessary.
The data shown here documents fifty years of consequence management. What it points toward is a fundamentally different starting point — one that asks not which drug to add next, but why the blood pressure required drugs in the first place.
Could Dietary Intervention Avert the Need for Drugs?
The evidence presented above points toward a compelling question: if insulin resistance is the upstream driver of hypertension, and if carbohydrate-driven hyperinsulinaemia is the primary sustaining mechanism of insulin resistance — then could addressing the diet directly, early enough, reduce or eliminate the need for antihypertensive medication?
The data cannot answer this definitively for populations. But a growing body of clinical evidence suggests that for many individuals, the answer could be yes.
A very low carbohydrate diet reduces postprandial insulin secretion, lowers fasting insulin, and improves HOMA-IR scores — often substantially, and within weeks. Lower insulin reduces renal sodium retention, which reduces blood volume and blood pressure through the precise mechanism that antihypertensive diuretics attempt to replicate pharmacologically. Intermittent fasting deepens these effects by extending the periods in which insulin remains low, allowing cellular insulin sensitivity to partially recover.
These are not speculative mechanisms. They are the same pathways that antihypertensive drugs target — only engaged through nutritional means rather than pharmaceutical ones. The question is not whether the mechanisms exist. It is whether individuals can access and sustain the dietary conditions that activate them.
Very Low Carbohydrate Protocol
Reducing dietary carbohydrates to below 50g per day substantially lowers postprandial insulin. This could reduce the primary hormonal driver of sodium retention and RAAS activation in insulin-resistant individuals, potentially reducing blood pressure without pharmacological intervention.
Intermittent Fasting
Extended fasting windows — whether 16:8 daily time-restricted eating or longer periodic fasts — sustain low-insulin states the body cannot achieve on frequent carbohydrate-containing meals. Emerging evidence suggests this could contribute to meaningful reductions in blood pressure in hypertensive individuals.
HOMA-IR as a Compass
Neither intervention can be evaluated without measurement. HOMA-IR — derived from fasting glucose and fasting insulin — provides a baseline and a trajectory marker. A score above 1.9 indicates developing insulin resistance. Retesting after 8–12 weeks reveals whether the metabolic root cause is being genuinely addressed.
Organic Whole Foods
Eliminating pesticide, herbicide, and antibiotic residues from the food supply removes a known driver of chronic low-grade inflammation and gut dysbiosis — both of which compound insulin resistance. Organic whole food nutrition is integral to the For Radiant Health approach alongside dietary carbohydrate reduction.
Important: Anyone currently taking antihypertensive medication who undertakes significant dietary change should do so under medical supervision. As insulin resistance improves, blood pressure may fall and medication doses that were previously appropriate could become excessive. Deprescribing, where appropriate, requires careful clinical oversight.
The fifty years of data shown in these graphs represent what happens when the root cause of a chronic disease is left unmeasured and unaddressed while its consequences are managed pharmaceutically. A different approach — one that begins with metabolic measurement and intervenes at the level of diet — could write a different fifty years.
- National Health and Nutrition Examination Survey (NHANES), Centers for Disease Control and Prevention — carbohydrate intake trends, hypertension and diabetes prevalence, antihypertensive medication use 1971–2021
- American Heart Association Heart Disease and Stroke Statistics — annual reports; antihypertensive prescribing prevalence
- CDC National Diabetes Statistics Report — type 2 diabetes prevalence trends 1971–2021
- National Vital Statistics System (CDC NVSS) — age-adjusted CVD and stroke mortality per 100,000, 1971–2021
- Ford ES et al. Explaining the decrease in US deaths from coronary disease, 1980–2000. New England Journal of Medicine 2007; 356(23):2388–98
- Egan BM et al. US trends in prevalence, awareness, treatment and control of hypertension, 1988–2008. JAMA 2010; 303(20):2043–50
- Mukete BN et al. Polypharmacy in older adults with hypertension: a comprehensive review. Journal of Clinical Hypertension 2016; 18(1):10–18
- Prevalence and trends of polypharmacy in US adults 1999–2018 (PMC10337167) — polypharmacy doubled from 8.2% to 17.1%; antihypertensives identified as primary driver
- EPA Report on the Environment — Cardiovascular Disease Prevalence and Mortality indicators, 1979–2018
- Pearson r values calculated from NHANES surveillance data series. All correlations significant at p < 0.05 except carb ↔ polypharmacy (r = 0.56, p = 0.059, trend-level significance)